Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

NCT02581657 is registered in ClinicalTrials.gov with PhaseBio Pharmaceuticals Inc. as lead sponsor.

NCT NCT02581657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
November 30, 2016
Enrollment
37 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus